|
|
Article: Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds.
- Article from:
- PR Newswire
- Article date:
- February 26, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST SETAUKET, N.Y., Feb. 26 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (BULLETIN BOARD: LIXT:OB) and its collaborator, the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), reported at the 1st International Conference on Drug Discovery and Development, Dubai, UAE, February 6, 2008, that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against medulloblastoma cells growing in culture and in a mouse model of cancer. Medulloblastoma is the most common brain tumor of children and is often fatal.
Dr. John S. ...
Related newspaper, magazine, and journal articles:
|
|
Article: Lixte Biotechnology Holdings Inc. Review in ...
M2 Presswire;
April 24, 2008 ;
700+ words
... ... traded companies Lixte Biotechnology Holdings Inc. was a flat trader ... April 23, 2008 Lixte Biotechnology Holdings announced that Dr ... Institutes of Health (NIH) and its collaborator, Lixte Biotechnology Holdings. Inc., reported ...
|
|